Navigation Links
Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes
Date:8/26/2014

SAN DIEGO, Aug. 26, 2014 /PRNewswire/ -- Profil Institute for Clinical Research, Inc., an early phase clinical research organization (CRO) focused on diabetes and obesity, announced today a milestone in clinical research for diabetes with the completion of more than 200 phase I – IIa clinical trials encompassing every clinically relevant drug class for the treatment of type 1 and type 2 diabetes.  

"The significance of this vast amount of research is what it represents for the public domain," said Dan Bradbury, former Amylin Pharmaceutical CEO, managing member of BioBrit, LLC, and member of Profil Institute's Board of Directors.  "Science driven results, as well as advances in clinical research methodologies by Profil Institute have contributed substantially to our understanding of new treatment opportunities and of how early phase clinical research in diabetes and obesity can be conducted in the most meaningful and efficient way.  As a result, we've seen significant progress toward better treatments for both type 1 and type 2 diabetes."

"The sense of urgency related to the diabetes epidemic is increasing with the rapid global rise of diabetes," said Dr. Marcus Hompesch, Profil Institute CEO.  "We've contributed important research to many current therapies providing exciting new treatment options for patients, but we have to continue to outpace ourselves to make an impact on diabetes worldwide.  We a have long, yet promising, path of opportunities in metabolic research as we turn our attention to biomarker discovery to predict and support the treatment of cardiometabolic diseases, as well as looking at novel combination therapies using existing drugs.

"More than a decade ago we decided to focus on diabetes, obesity and cardiometabolic clinical research because, as a group of scientists, that was at the center of our research and was where we hoped to make the most significant impact on science and patient care.  Today we're pleased that through our commitment to science, clinical research and drug development, we have built the teams, infrastructure, technology and expertise that have allowed us to accumulate the knowledge and experience to benefit diabetes research as a whole."

Profil Institute is the only CRO in the U.S. therapeutically and scientifically focused exclusively on early phase diabetes and obesity clinical research and development.  Profil Institute has invested in its scientific expertise, including doctorate level scientists that make up more than 20% of Profil Institute's workforce, and in advancing its Automated Glucose Clamp technology and other key research methods.  The company's experience in early phase clinical studies includes every clinical relevant drug class, as well as nearly all modes of administration and blood glucose monitoring devices.  Of the 200 early phase clinical studies completed, 45% of those studies involved study participants with type 2 diabetes, 20% with type 1 diabetes, 20% with healthy study participants, and 15% involved specialized populations, including participants with cardiovascular disease, kidney disease or insulin resistance.

About Profil Institute for Clinical Research, Inc.

Profil Institute for Clinical Research, Inc. is a science driven, early phase clinical research organization (CRO) focused on diabetes and obesity.  It is renowned for its scientific expertise, depth of services, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes.  The company provides end-to-end early phase services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.

Profil Institute's expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices.  The company's clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia. 

Profil Institute is also recognized internationally as an innovator of methodologies to improve the quality of metabolic research, including its Automated Glucose Clamp technology.  As the leading early phase CRO focused on diabetes and obesity, Profil Institute is driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners  and its Metabolic Research Partners™ program. 

For more information, please visit www.profilinstitute.com.


'/>"/>
SOURCE Profil Institute for Clinical Research, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
2. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
3. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
4. Abaxis Announces the Launch of Kidney Profile Plus Panel
5. NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study
6. Group Florence Nightingale Increases Radiosurgery Profile with Acquisition of Turkeys First Leksell Gamma Knife Perfexion System
7. Varian Medical Systems Selected by Leading Russian Development Foundations to Take Part in High-Profile Supplier Event
8. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at RnRMarketResearch.com
9. High Profile HealthCare Companies: Leading Pharma Company Secures New Patents
10. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
11. Fortune Magazine Profiles ArcView Group, Co-founded by Steve DeAngelo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... PLAD, Inc. (OTC Pink: PLAD) is pleased to announce ... company targets, are adding key personnel to their national ... United States Patent and Trademark Office for the characters ... of PLAD, Inc.  In January, PLAD established their presence ... with two new customers, Cumberland Goodwill EMS and Meadville ...
(Date:2/11/2016)... 2016  M3 Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery , ... an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said the ...
Breaking Medicine Technology:
(Date:2/11/2016)... City, FL (PRWEB) , ... February 11, 2016 ... ... announced the commencement of a master charity program created to assist the people ... 60 days, working closely with nonprofit organizations and community leaders. Their hope is ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance Group, serving ... introduces a new charity campaign to raise funds for Ronald McDonald House Charities. ... https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally renowned nonprofit ...
(Date:2/11/2016)... ... ... Be Well Medical Group (Be Well) is pleased to announce ... South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is a concierge ... of their homes, offices or at the practices’ local office. It is also one ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling for American ... and wellness best practices in the past couple of decades, and food manufacturers ... Heart Month, which acts as an exceptional opportunity to revise food labels and ...
(Date:2/10/2016)... ... 10, 2016 , ... President Obama’s budget proposal yesterday enables ... medical services via telehealth, estimated to generate more than $160 million in savings ... many years. Although there is more to be done, this represents an ...
Breaking Medicine News(10 mins):